16.70
+2.14%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adimmune
Its shares trade on Taiwan Stock Exchange under the ticker 4142.TW. It has been listed since 29 September 2010. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.40bn and a net loss of TWD 239.9m. At that date it held total assets of TWD 8.19bn and shareholders' equity of TWD 4.94bn.
Adimmune Corp. engages in the manufacturing and sales of influenza vaccine. The company is headquartered in Taichung, Taichung. The company went IPO on 2010-09-29. The firm's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The firm distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Sept 2010
- Employees
- 551
- Website
- adimmune.com.tw ↗
Leadership
Pay as last reported
- Mr. Chin-Chuan ChangChief Operating Officer, since 2019TWD 5.7m
- Mr. Fei PanDeputy General Manager, Chief Legal OfficerTWD 5.2m
- Mr. Jin-Yi ChiouDeputy General Manager-General Manager's Office
- Mr. Yueh-Peng HungDeputy General Manager-Business Division
- Ms. Hui-Wen WangDeputy General Manager-New Technology and Process Development Division
- Mr. Jing-Yao LinCorporate Governance Officer
- Mr. Yuan-Hou YenDeputy Chief Operating Officer
- Mr. Hsiao-Po HsuDirectorTWD 3.0m
- Mr. Chi-Heng LinDirectorTWD 35,000
- Jong-Rong LinDirector
- Mr. Jung-Chin LinDirector
- Mr. Te-Sheng LinDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adimmune Corp manufactures influenza vaccines for domestic and international markets including Asia, Europe, and Africa.
- The company's product portfolio includes Japanese encephalitis vaccines and H1N1 influenza vaccines.
- Adimmune Corp has 551 employees focused on biotechnology and vaccine manufacturing.
Weaknesses
- Adimmune Corp's products are limited to specific vaccines like tetanus and tuberculin without broader applications.
- The company's distribution is primarily domestic with limited international market penetration.
- Adimmune Corp's business relies on a narrow range of vaccine products without diversification.
Opportunities
- Expanding into new markets in Asia, Europe, and Africa for influenza vaccine sales.
- Increasing demand for H1N1 influenza vaccines in global health initiatives.
- Growing biotechnology sector in Taiwan supporting vaccine research and development.
Threats
- Competition from other biotechnology firms in the Health Care sector.
- Regulatory challenges in vaccine distribution across different countries.
- Potential market saturation in the influenza vaccine segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.